Skip to main content
. 2017 Jul 3;9(9):1294–1313. doi: 10.15252/emmm.201607315

Figure EV3. Peptide aldehyde proteasome inhibitor (MG132, MG115), and peptide boronate (MG262) but not other analogs (bortezomib and carfilzomib) elicited efficient progerin clearance.

Figure EV3

  1. MG132 and MG262 induced clearance of progerin. A representative Western blotting experiment in whole lysates of HGPS fibroblasts showing progerin and GAPDH expression in MG132‐ and MG262‐treated HGPS cells at the indicated concentrations relative to DMSO‐treated (−) cells for 24 h (Control). (n = 5).
  2. Western blotting evaluation of lamin A/C, progerin and GAPDH in whole lysates from HGPS fibroblasts untreated (−) or treated with bortezomib or carfilzomib for 24 h at indicated concentrations. (n = 4).
  3. Left panels: progerin, actin, and GAPDH expressions in whole lysates from HGPS fibroblasts treated for 48 h with DMSO (Ctrl) or 5 μM MG132, MG115, MG262, bortezomib (BTZ), or carfilzomib (CFZ). Right panels: Progerin expression levels relative to DMSO‐treated cells were normalized to actin values using ImageJ software. (n = 6).
  4. Proteasome activities (trypsin: Z‐LRR aminoluciferin, chymotrypsin: Suc‐LLVY aminoluciferin and caspase‐like: Z‐nLPnLD‐aminoluciferin) in HGPS fibroblasts upon 24 h MG132, bortezomib, or carfilzomib treatment, used at 5 μM. (n = 4).
Data information: Results in (C, D) are expressed as mean ± SEM, Student's t‐test, **P < 0.01, ***P < 0.001); the exact P‐values are indicated in Appendix Table S1. Luminescence is determined as relative light units (RLU).